Our clients include over 2 500 leading global metals, pipe, woodworking and construction materials companies, whose daily business is dependent on transportation of large and heavy cargo by trucks, by railways or by ships. We produce our strap according to international standards in Europe’s most modern factory in Kostroma, Russia, with over 27 years of experience.
We produce our PET and steel strap on the most modern European production lines in Kostroma. Our PET strap capacity is 15 000 MT, and steel strap capacity – 40 000 MT.
Specta was founded in 1993 by Mr. Erik Helin and Mr. Teppo Viherkoski with a mission to optimize the quality of industrial transport packaging. Specta was one of the pioneers in the Russian market, and along with the growing Russian heavy industry, its sales network gradually grew to cover all Russia from St Petersburg to Vladivostok, and eventually also to CIS countries.
In 2007 Specta invested in a modern steel strap factory in Kostroma, about 300 km North-East of Moscow. During the years, Specta widened its product portfolio and know-how to become a comprehensive industry packaging solutions provider, with a product range from PET and steel strap to accessories, from manual strapping tools to automatic machines. Currently Specta has a global sales organization and reseller network all over the world.
2005 – VolgaStrapSteel strap plant was built in the town of Kostroma
Standard-quality steel strap
Specta Prima is a standard-quality strap for manual and automatic packaging of processed wood products, cold-rolled sheet and coil steel, non-ferrous metal ingots, and building materials.
High-strength strap designed for bundling of heavy products such as cast steel stock, rolled sections, and wire rods
Specta Forte Modex is a high-strength strap designed for bundling of heavy products such as cast steel stock, rolled sections, and wire rods. Finished products can be packed at high temperatures. The strap may be used for packaging of products that are subjected to moderate dynamic loads during transportation and storage.
Packaging strap specially designed for heavy-duty applications
Specta Factor is a packaging strap specially designed for heavy-duty applications. It is used for packing steel pipes, rolled sections and hot-rolled steel up to 6 mm thick. Finished products can be packed at high temperatures.
High tensile steel strap suitable for packaging of heavy and hot products
Specta Delta is a high tensile steel strap suitable for packaging of heavy and hot products: hot rolled metals with thickness up to 25mm, metal pipes, ingots of different alloys, bars, rods etc. It is used for more tense packing of transported products in severe conditions in ferrous and non-ferrous metallurgy and construction industry.
F2 Ventures is a healthcare investment platform focused on arbitrage opportunities across the biotech sector, targeting innovation at the right stage for maximum impact.
Executive Chairman of the Board
David is a proven 30-year veteran in the biopharmaceutical industry, having grown and operated several successful biotechnology companies. During his 10-year tenure at Alexion Pharmaceuticals, where he served as Chief Executive Officer, Chief Operating Officer and Chief Commercial Officer, he led the pipeline expansion from a single-product to multi-product company, resulting in Alexion’s inclusion into the S&P500. Prior to Alexion, David spent nearly 20 years at Amgen, Biogen, and Eyetech in executive and senior leadership roles.
David also serves as Chairman and CEO of ElevateBio, an Independent Chairman of Scholar Rock (SRRK) and iTeos Therapeutics as well as an Independent Director of Seer. He holds a BA in psychology from the University of New Hampshire.
SAB Member, Director of Baylor College of Medicine’s Center for Cell and Gene Therapy
Dr. Heslop is Professor of Medicine and Pediatrics and Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children’s Hospital. She is the Dan L. Duncan Chair and the Associate Director of Clinical Research at the Dan L. Duncan Cancer Center. Trained as a physician-scientist, Dr. Heslop is a prominent figure engaged in translational research focusing on adoptive T cell immunotherapy to improve hematopoietic stem cell transplantation and cancer therapy. In collaboration with Drs.Brenner and Rooney, her initial studies were the first to demonstrate the feasibility of using EBV-specific T cells to prevent and treat EBV-associated malignancy in stem cell transplant patients, thereby validating the safety and efficacy of adoptive T cell transfer as a therapeutic modality.
Chief Scientific Officer
Dr. Ann Leen co-founded and serves as Chief Scientific Officer of AlloVir. For more than 20 years, Dr. Leen has led innovative discovery and translational research focused on developing novel T cell-based therapies. Her research has enabled multiple cell therapy programs to move from bench to bedside. She is currently the principal investigator (PI) on 5 investigator-initiated Investigational New Drug (IND) studies and over the past 10 years has served as PI on more than 10 clinical trials using “first in man” cell therapies for patients.
Ann received her B.S. in Biochemistry at the University of College Cork in Cork, Ireland and her Ph.D. in Immunology at the CRC Institute for Cancer Studies in Birmingham, UK.
SAB Member, Professor of Pediatrics, Baylor College of Medicine
Dr. Rooney is a Professor in the Departments of Pediatrics, Molecular Virology and Microbiology, and Immunology and Director of Translational Research Laboratories at the Center for Cell and Gene Therapy at Baylor College of Medicine. Dr. Rooney is renowned virologist and immunologist who, in collaboration with Drs. Heslop and Brenner, was the first to demonstrate that antigen-specific T cells generated in the laboratory could prevent and cureviral-associated malignancies in humans following hematopoietic stem cell transplantation. She has been key in extending this successful strategy to develop and clinically test a range of post-transplant viral infections and diseases.
Associate Professor, Baylor College of Medicine
Dr. Juan Vera has more than 15 years of experience performing research in the field of adoptive T cell therapy and has made several contributions in the field, specifically in the areas of genetic engineering T cells manufacture process optimization. He has extensive expertise developing and streamlining therapeutic candidates from the research bench to the cGMP facility while ensuring robust production and scalability.
In collaboration with Wilson Wolf Manufacturing, Dr. Vera has been instrumental in the design and testing of the G-Rex® cell culture platform and pioneered its use for the large-scale production of T cells. He is a Co-Investigator on a number of clinical trials for T cell therapy in both infectious disease and cancer. His recent focus is on developing strategies to enhance the T cell function by protecting tumor-targeted T cells from the immunosuppressive effects of the tumor microenvironment in order to enhance in vivo persistence and function.
Managing Partner, F2 Ventures
In 2003, Dr. Jovan co-founded F2 Ventures, a biotech venture capital platform and has since served as its Managing Partner. Prior to joining F2 Ventures, Dr. Jovan was a partner at MPM Capital. Dr. Jovan currently serves on the boards of directors of Damon Runyon Cancer Center Research Foundation, TriNetX, Inc. and Cullinan Oncology. Dr. Jovan received her Ph.D. in biophysical chemistry from the University of Cambridge and was a post-doctoral fellow at Harvard University.
F2 Ventures is a healthcare investment platform focused on arbitrage opportunities across the biotech sector, targeting innovation at the right stage for maximum impact.
Allovir’s President and Chief Financial Officer
Vikas Sinha, our President and Chief Financial Officer, brings over 25 years of experience in executive finance roles within the biopharmaceutical industry. He served as the Chief Financial Officer of Alexion Pharmaceuticals for more than 11 years, where he oversaw the global expansion of the company across 50 countries and revenue growth to more than $3 billion. Prior to joining Alexion, Vikas held various positions with Bayer AG across the world, including CFO, Bayer Pharma, North America and CFO, Bayer Yakuhin, Japan. He also serves as Chief Financial Officer of ElevateBio and an Independent Director and Audit Committee Chair at Verona.
Vikas received his M.B.A. from the Asian Institute of Management, Manila, Philippines. He is a qualified Chartered Accountant and associate member of the Institute of Chartered Accountants of India and a Certified Public Accountant in the UnitedStates.
British doctor
Dr. Brenner is the founding director of the Center for Cell and Gene Therapy and the Fayez Sarofim Distinguished Service Professor at Baylor College of Medicine in the Departments of Medicine, Pediatrics, and Human and Molecular Genetics. He is also a member of the Texas Children’s Cancer and Hematology Center, the Stem Cell and Regenerative Medicine Center, and the Dan L. Duncan Comprehensive Cancer Center at Baylor. Over the past 30 years, Dr. Brenner has devoted his career as a physician-scientist to the field of stem cell transplantation through the therapeutic use of T cell immunologic approaches and genetic engineering strategies. He served as Editor-in-Chief of Molecular Therapy and as former President of the American Society for Gene and Cell Therapy (ASGCT)and International Society for Cell Therapy.
CEO, Wilson Wolf Manufacturing Corporation
Mr. Wilson has over 30 years of experience in the design, development and manufacture of products for the field of biotechnology, including cell culture devices and bioreactors. Mr. Wilson has obtained over 50 related patents with numerous patents currently pending. He is the co-inventor of the G-Rex® platform, which has revolutionized T cell manufacturing practices with its simple, reliable and scalable cell production. Mr. Wilson is also the co-inventor of the CELLineTM product line. Prior to co-founding Wilson Wolf Manufacturing and ViraCyte, Mr. Wilson was a principal mechanical engineer at Cellex Biosciences (now The Cell Culture Company) where he contributed to the world’s first commercially available fully-automated hollow fiber bioreactor cell culture system. Mr. Wilson has a BA in Business Administration and a BA in Economics from Hamline University in Minnesota and a B.S. in Mechanical Engineering from the University of Minnesota.